New hope for HER2-Mutant lung cancer: phase 3 trial launches

NCT ID NCT07178795

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing a new drug called BL-M07D1 against standard chemotherapy (pembrolizumab plus platinum chemo) as a first treatment for people with advanced or metastatic non-squamous non-small cell lung cancer that has a HER2 mutation. About 440 participants will be randomly assigned to receive either the new drug or standard therapy. The main goal is to see if BL-M07D1 can delay cancer growth or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M07D1 (a drug given by IV every 3 weeks)
What this could lead to: If it works, this could offer a new first-line treatment option for people with a specific type of advanced lung cancer that has a HER2 mutation.
What could go wrong: This is an early Phase 3 trial, so results are not yet known. The new drug may not be more effective than current standard therapy and could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.